Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

About the trial

Sponsor

Sanofi (with Kymera Therapeutics, Inc.)

Tested

SAR444656 (KT-474) (drug), Placebo (drug)

Dates

Started 2023-11-09; completion 2025-11-20

Results posted

Yes

This was a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who were inadequately controlled with topical therapies or for whom such topical therapies were inadvisable and who were candidates for systemic therapy. Participants were randomized to receive SAR444656 dose 1, dose 2, dose 3 or matching placebo. Participants who met inclusion/exclusion criteria were stratified for randomization by severity of AD (moderate \[baseline EASI score \<22\] versus severe \[baseline EASI score ≥22\]). The total duration of study was approximately 24 weeks, including 1 to 4 weeks for screening, 16 weeks for…

From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $595,795 in research payments for this study in 2025 (140 payments).

Products named: Dupixent

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.